The Three-Layer Energy Stack
This stack is aimed at cellular energy metabolism in the mitochondria. Three compounds, three proposed mechanisms; no human trial has tested the combination.
🧪 Buy NAD+ at Swiss Chems →Track your vials and inventory on paper
Printable vial and inventory sheets for your own research records. Every value is entered by you. Free to build and preview; $5/month to unlock printing.
Stimulants vs. Metabolic Targets
Stimulants such as caffeine act mainly on the nervous system to raise alertness. This stack is aimed at a different target (cellular energy metabolism), though that approach has not been tested in humans.
Stimulant Model
Stimulants raise alertness. Their primary action is on the nervous system rather than mitochondrial energy metabolism.
Mitochondrial Model
Fix the power plants themselves. Better efficiency, less degradation: the goal, not a demonstrated human outcome.
NAD+ Decline With Age
NAD+ levels decline during the aging process, a decline linked to defects in nuclear and mitochondrial function (Imai & Guarente, 2014, Trends in Cell Biology). How steep the decline is varies by tissue.
Three Layers, One System
Each compound targets a different layer of mitochondrial energy production. Together, they are aimed at fueling, signaling, and keeping the NAD+ precursor nicotinamide available for NAD+ synthesis, a combination no study has tested.
NAD+ (NMN / NR)
NAD+ is a coenzyme in ATP production and is consumed by PARP and sirtuin enzymes. NMN and NR are taken to raise NAD+; whether that makes mitochondria produce ATP more efficiently in humans has not been shown, and human translation is still being tested (Yoshino et al., 2018).
MOTS-c
A mitochondrial-derived peptide that, in mice, activated AMPK and improved insulin sensitivity and metabolic homeostasis (Lee et al., 2015).
5-Amino-1MQ
An NNMT inhibitor. Inhibits NNMT, an enzyme that methylates nicotinamide, diverting it away from NAD+ production. Plus: fat loss seen in diet-induced obese mice.
NAD+ — Fuel Support
NAD+ is the critical coenzyme in every cell that converts nutrients into ATP, your body's energy currency. It is also used by sirtuins (NAD+-dependent enzymes) and by PARP DNA-repair enzymes. But NAD+ levels decline with age.
ATP Production
NAD+ shuttles electrons in the mitochondrial electron transport chain.
DNA Repair
PARPs consume NAD+ to fix DNA damage.
Sirtuin Activation
Sirtuins (SIRT1–7) are NAD+-dependent enzymes that regulate metabolism, inflammation, and cellular stress response.
Cellular Signaling
NAD+ is consumed in signaling reactions (CD38, SARM1).
NAD+ Precursor Comparison
Three main ways to raise NAD+, each with different trade-offs.
| Precursor | Route | Bioavailability | Speed | Cost | Evidence |
|---|---|---|---|---|---|
| NMN | Oral / sublingual | Direct NAD+ precursor | Not established | $$ | Preclinical; human translation still being tested (Yoshino et al., 2018) |
| NR (Niagen) | Oral | Not reviewed on this page | Not established | $$ | Human trials (not reviewed on this page) |
| IV NAD+ | Intravenous | Direct: bypasses digestion | Not established | $$$$ | Not reviewed on this page |
Research: Imai & Guarente (2014) established the NAD+/sirtuin axis as central to aging. Yoshino, Baur & Imai (2018), a Cell Metabolism review, summarized preclinical work in which NMN and NR supplementation ameliorated age-associated conditions, and noted that whether these results translate to human health is still being tested.
MOTS-c — Metabolic Signal
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, making it one of the first known mitochondrial-derived signaling molecules. In mice, it acted on skeletal muscle, inhibiting the folate cycle and activating AMPK, and prevented diet-induced obesity and insulin resistance (Lee et al., 2015).
Mitochondrial Biogenesis
Often described as a biogenesis signal, but the core mouse study (Lee et al., 2015) showed AMPK activation via the folate cycle, not the building of new mitochondria.
AMPK Activation
In mice (Lee et al., 2015), MOTS-c activated AMPK, the master metabolic sensor involved in fat oxidation and glucose uptake. Human data are limited.
Metabolic Flexibility
Proposed to affect how cells switch between fat and glucose as fuel. Not measured in the studies cited on this page.
Exercise Link
MOTS-c levels rise during exercise. Whether supplementation reproduces any effect of exercise in humans has not been tested.
MOTS-c Research Highlights
Lee et al. (2015) — Cell Metabolism
First identification of MOTS-c as a mitochondrial-encoded signaling peptide. Showed MOTS-c regulates metabolic homeostasis and prevents age-dependent and diet-induced insulin resistance in mice.
Reynolds et al. (2021) — Nature Communications
Demonstrated that MOTS-c is exercise-induced, and that treatment with MOTS-c improved physical performance in aged mice, suggesting it as a regulator of age-dependent physical decline.
5-Amino-1MQ — NNMT Inhibitor
5-Amino-1MQ is a small-molecule NNMT inhibitor. NNMT (nicotinamide N-methyltransferase) is an enzyme that methylates nicotinamide, diverting it away from NAD+ production. In cultured fat cells, NNMT inhibitors raised intracellular NAD+ (Neelakantan et al., 2018).
NNMT Inhibition
NNMT methylates nicotinamide, diverting it away from NAD+ production. 5-Amino-1MQ selectively blocks this enzyme, keeping more nicotinamide available for NAD+ synthesis.
Intracellular NAD+
NNMT inhibitors increased intracellular NAD+ in cultured fat cells. Whether 5-Amino-1MQ makes NMN/NR supplementation more effective has not been tested.
Fat Loss in Mice
In humans, NNMT expression in white adipose tissue was about twofold higher in type 2 diabetes and tracked insulin resistance (Kannt et al., 2015). In diet-induced obese mice, NNMT inhibition reduced fat mass and adipocyte size (Neelakantan et al., 2018). Not tested in humans.
Membrane Permeability
5-Amino-1MQ is a small molecule. Its compound class showed high membrane permeability in cell assays (Neelakantan et al., 2018); the mouse study gave it systemically, and no human oral data have been published.
Key Research
Neelakantan et al. (2018) — Biochemical Pharmacology
Developed selective, membrane-permeable NNMT inhibitors including 5-Amino-1MQ. Showed reduction in fat mass and adipocyte size in diet-induced obesity mouse models without affecting food intake.
Kannt et al. (2015) — Diabetologia
Established the link between NNMT expression in adipose tissue and insulin resistance, providing the rationale for NNMT inhibition as a metabolic intervention target.
The Combination Rationale
The rationale is that the three could reinforce each other: supply NAD+ precursors, signal metabolic adaptation (shown in mice), and slow the diversion of nicotinamide away from NAD+. That loop is a hypothesis; no study has tested it.
NAD+
Coenzyme in ATP production
MOTS-c
Activates AMPK (mice)
5-Amino-1MQ
Raised NAD+ in fat cells (in vitro)
Proposed Loop
NAD+ is a coenzyme in mitochondrial energy production; that precursors make mitochondria more efficient in humans is unproven. MOTS-c activated AMPK in mouse muscle. 5-Amino-1MQ inhibits NNMT, which diverts nicotinamide away from NAD+. Whether they amplify each other is untested: no human trial has studied this combination.
Baseline, Not Stimulation
This stack targets baseline metabolism rather than stimulation; whether or how long any effect takes in humans has not been studied.
Different Targets
Layer 1 is substrate supply. Layer 2 is metabolic signaling. Layer 3 blocks NNMT, which diverts the precursor nicotinamide away from NAD+ production. Layers 1 and 3 both concern NAD+ supply.
Dosing Protocol
Informational only, not prescriptive. No human dosing has been established for MOTS-c or 5-Amino-1MQ, and this page cites no dosing source for NMN, so no doses are listed. Always consult a healthcare provider before starting any protocol.
Protocol Notes
- No titration schedule or cofactor pairing has been studied for this stack
Who Reads About This Stack
Readers of this page are usually interested in research on cellular energy metabolism rather than stimulation, often in the topics below. MOTS-c and 5-Amino-1MQ are labeled for research use only, no human dosing has been established, and whether this stack works in humans is untested.
Chronic Fatigue
Persistent low energy despite adequate sleep and nutrition (not studied for this stack; see a clinician first)
Age-Related Decline
NAD+ levels decline during aging (Imai & Guarente, 2014)
Brain Fog
Cognitive effects of this stack have not been studied
Athletes
Effects on mitochondrial density or performance have not been tested in humans
Recovery
NAD+ feeds sirtuin and PARP repair pathways; recovery benefits from this stack have not been tested in humans
Monitoring Your Progress
Subjective energy improvements can be placebo. These metrics can track change over time, but no study cited here shows they can confirm whether this stack works.
-
NAD+ Blood Test
Intracellular NAD+ testing measures blood NAD+ levels. No study cited here shows such a test can confirm whether this stack works.
-
Subjective Energy Tracking
Daily 1–10 energy rating at consistent times (morning, afternoon, evening). Look for a sustained baseline shift, not day-to-day variation.
-
Body Composition
5-Amino-1MQ's fat loss has only been shown in diet-induced obese mice. If you want to check for an effect, track body fat percentage and lean mass with a DEXA scan or smart scale at monthly intervals.
-
Cognitive Performance
If you want to track cognition, use the same tasks each time (e.g. reaction-time tests). The stack's cognitive effects have not been studied, so this tracks change; it does not imply a benefit.
-
Sleep Quality
Wearable data (HRV, deep sleep duration, recovery scores) tracks sleep trends; it does not measure mitochondrial function or cellular repair.
Stack Supplements & Tools
Related supplements and tracking tools. None has been tested as part of this stack.
Affiliate links support HighPeptides at no extra cost.
Research Peptides & Compounds
Swiss Chems sells MOTS-c, 5-Amino-1MQ, and other compounds labeled for research use only, not for human use. No human dosing has been established for MOTS-c or 5-Amino-1MQ.
Browse Swiss Chems →Related Resources
Key Takeaways
What We Know
- NAD+ levels decline during aging (Imai & Guarente, 2014)
- MOTS-c is a mitochondrial-encoded signaling peptide with published mouse studies (Lee et al., 2015; Reynolds et al., 2021)
- 5-Amino-1MQ selectively inhibits NNMT and reduces fat mass in animal models
What We Don't
- No human RCTs have tested this specific three-compound stack together
- MOTS-c human clinical trial data is still very limited
- 5-Amino-1MQ has no published human trials; evidence is preclinical
- Long-term safety profiles for combination use are unknown
- Optimal dosing ratios for synergistic effects haven't been established
More Peptide Guides
Beginner explainers, safety evidence, and protocol write-ups on other topics. None of them give MOTS-c or 5-Amino-1MQ doses, because no human dosing has been established for either.
Browse the Guides →Educational content only. Not medical advice. This page is for informational purposes. The mitochondrial energy stack described here combines dietary supplements (NMN), research peptides (MOTS-c), and investigational compounds (5-Amino-1MQ). None of these combinations have been FDA-approved for any condition. 5-Amino-1MQ and MOTS-c are sold for research purposes only. The research cited includes preclinical and early-stage studies — do not interpret as established treatment guidelines. Always consult with a qualified healthcare provider before starting any supplementation or peptide protocol.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.